Reneo Pharmaceuticals Stock Quote RPHM - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.71

Bid

1.70

Ask

1.85

Volume

0.00 Day's Range 0.00

0.9801 52 Week Range 10.74

Market Cap

56.963M

Previous Close

1.71

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

167,584

Shares Outstanding

33,311,787

Dividend Yield

PE Ratio

-0.74

Earnings Per Share (EPS)

-2.32

Revenue

Net Profit

-77.39M

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing ... Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

reneopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Reneo Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RPHM. The last closing price for Reneo Pharmaceuticals was $1.71. Over the last year, Reneo Pharmaceuticals shares have traded in a share price range of $ 0.9801 to $ 10.74.

Reneo Pharmaceuticals currently has 33,311,787 shares outstanding. The market capitalization of Reneo Pharmaceuticals is $56.96 million. Reneo Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.74.

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.05	3.01204819277	1.66	1.77	1.62	121504	1.67547835	CS
4	-0.01	-0.581395348837	1.72	1.92	1.62	108272	1.70234838	CS
12	0.06	3.63636363636	1.65	1.92	1.55	167584	1.66094768	CS
26	-6.3	-78.6516853933	8.01	8.19	0.9801	632915	2.0052715	CS
52	-8.76	-83.6676217765	10.47	10.74	0.9801	395482	3.13890664	CS
156	-12.98	-88.3594281824	14.69	14.95	0.9801	170459	3.76164352	CS
260	-13.59	-88.8235294118	15.3	16.83	0.9801	170172	3.95919095	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NUVOHoldco Nuvo Group DG Ltd	7.99 (3,531.82%)	90
APVOAptevo Therapeutics Inc	$ 1.32 (37.50%)	1M
TRSGTungray Technologies Inc	$ 7.74 (25.85%)	100
SEELSeelos Therapeutics Inc	$ 0.3743 (24.77%)	13.46k
ENVXEnovix Corporation	$ 7.99 (22.73%)	45.21k
FRSHFreshworks Inc	$ 13.17 (-27.84%)	9.62k
RELYRemitly Global Inc	$ 14.58 (-16.88%)	134
PLTNPlutoniam Acquisition Corporation	$ 7.80 (-14.75%)	445
FBYDFalcons Beyond Global Inc	$ 8.00 (-14.35%)	16
DASHDoorDash Inc	$ 109.61 (-14.00%)	2.4k
FFIEFaraday Future Intelligent Electric Inc	$ 0.0523 (13.45%)	1.82M
APVOAptevo Therapeutics Inc	$ 1.32 (37.50%)	1M
SQQQProShares UltraPro Short QQQ	$ 11.90 (-2.62%)	473.03k
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 8.42 (5.12%)	384.89k
ALLRAllarity Therapeutics Inc	$ 1.44 (5.11%)	223.66k